Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stevia venture

This article was originally published in The Tan Sheet

Executive Summary

A joint venture by stevia producer GLG Life Tech and fitness product firm Weider Global Nutrition aims to bring dietary and tabletop supplements made with stevia leaf extracts into international markets, GLG announces Sept. 9. GLG Weider Sweet Naturals Corp. will leverage the stevia extraction expertise of Vancouver, British Columbia-based GLG, and the sales and distribution capacities of Salt Lake City-based Weider to "provide consumers a great tasting, natural and zero-calorie alternative to artificial sweeteners and calorie-laden sugar," says GLG President Brian Palmieri. Though multiple U.S. companies are either marketing or developing stevia-based sweeteners, FDA has not declared the substance safe as a food additive and consumer groups have questioned stevia safety data (1"The Tan Sheet" Sept. 1, 2008, p. 16)

You may also be interested in...



Stevia Safety Certifications Lacking FDA OK Called Into Question

The Center for Science in the Public Interest maintains FDA's process for certifying a substance as generally recognized as safe is insufficient and has left the door open for the marketing of potentially unsafe sweeteners made from the stevia leaf

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

Topics

UsernamePublicRestriction

Register

PS102108

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel